Navigation Links
Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
Date:10/23/2008

NEW YORK, Oct. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has received notice from The Nasdaq Stock Market ("Nasdaq") stating that Nasdaq Marketplace Rule 4310(c)(4), which requires companies to maintain a minimum bid price of $1.00 per share, has been temporarily suspended. Based on this action, Nasdaq informed the Company that it now has until January 23, 2009, to achieve compliance with Rule 4310(c)(4).

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
5. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
6. Keryx Biopharmaceuticals Receives Nasdaq Notification
7. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
8. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd.) (NASDAQ: ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... and nutritional products, today announced their collaboration to achieve the first-ever ... China to the United States ... ...
(Date:2/22/2017)... SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, ... UTHR ) today announced its financial results for ... "Our annual 2016 financial results reflect ... and earnings exceeded $700 million," said Martine Rothblatt, ... "These financial results strengthen our ability to develop ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... biotech research and development (R&D), today announced the establishment of Genedata Limited as ... Director Kevin Teburi, a recognized expert in life science informatics. Creating the UK ...
(Date:2/21/2017)... ... February 21, 2017 , ... Creation ... manufacturing solutions for original equipment manufacturers (OEMs) , today announced it has received ... third consecutive year winning in its category of electronics manufacturing services (EMS) providers ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):